The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The 27 greenfield labs across the country ensure timely and accurate reporting
Dasatinib Tablets is indicated for the treatment of (i) newly diagnosed adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
A new weapon in the global fight against malaria
The newly inaugurated facility bridges this gap by offering metro-grade treatment closer to home
Subscribe To Our Newsletter & Stay Updated
